**Core tip:** Microscopic enteritis (ME) is an inflammatory condition, which is characterized by increased intraepithelial CD3 lymphocytes in the duodenum and can be due to both gluten and non-gluten related diseases. It is often difficult to achieve a final diagnosis in cases of ME, therefore the assessment of baseline mucosal molecular pattern may be helpful. In this study, we demonstrated that tissue transglutaminase and interferon gamma may predict the development of Celiac Disease more than Gluten Sensitivity with high specificity, despite an expected low sensitivity.

INTRODUCTION
============

Duodenal lymphocytosis (DL) is a condition characterized by a pathologic infiltration of lymphocytes in the epithelium (IELs) of duodenal mucosa\[[@B1]\]. It is not a single entity, since several conditions may underlie this picture. The main associated disorders may be gluten related (Celiac disease - CD; Non celiac gluten sensitivity - NCGS; and Wheat allergy - WA) and non-gluten related (Irritable bowel syndrome - IBS; infectious or parasitic diseases; autoimmune disorders: vasculitides, connective tissue diseases and inflammatory bowel disease; immunoglobulin deficiencies; drug damage)\[[@B2]-[@B8]\]. Therefore, DL may be considered as an "umbrella term" rather than a single entity. Recently, the Bucharest Consensus has proposed "Microscopic enteritis (ME)" as an alternative term to DL, and has reviewed and standardized an algorithm for its diagnosis and treatment\[[@B9],[@B10]\].

In the ME scenario, it is well known that CD is an autoimmune enteropathy triggered by the ingestion of gluten and represents the most common cause of intestinal malabsorption and villous atrophy\[[@B11]\]. NCGS \[or simply gluten sensitivity (GS)\] is a disorder showing intestinal and extra-intestinal symptoms related to the ingestion of gluten containing food, in subjects not suffering from either CD or WA\[[@B12]\]. It is an emerging gluten related cause of ME and intestinal symptoms, with an increasing rate of diagnosis\[[@B13],[@B14]\]. However, the spectrum of ME encompasses even non gluten-related disorders. For instance, IBS may show increased IELs as well as organic diseases\[[@B1],[@B15]\]. For this reason, it is often difficult to formulate a differential diagnosis in ME, and the diagnostic *iter* may be long and time consuming. This aspect is of relevance especially for GS, whose diagnosis is essentially clinical. Moreover, the clinical manifestations of GS often overlap with IBS, and this is a diagnostic challenge\[[@B16],[@B17]\]. A previous experience of our group found that IELs count of 15-25 IELs/100 enterocytes, autoimmune thyroiditis, folate deficiency and diarrhea may be predictive factors for GS\[[@B18]\], but a reliable marker has not been discovered yet despite the report that GS is characterized by the upregulation of toll-like receptor 2 (TLR2)\[[@B19]\].

In our experience, a IELs infiltrate \> 15 per 100 enterocytes paralleled an enhanced expression of pro-inflammatory cytokines, in particular interferon gamma (IFNγ), in subjects with suspected seronegative CD\[[@B20]\]. Therefore, a pro-inflammatory status may underlie CD-related ME and the intestinal assessment of baseline mucosal molecular pattern could likely give useful information about ME underlying conditions. In detail, tissue Transglutaminase 2 (tTG2), IFNγ, TLR2 and Myeloid Differentiation factor 88 (MyD88) have been suggested as potential targets in this field\[[@B19]\]. tTG2 is the main autoantigen involved in the pathogenesis of CD, and it has been demonstrated that it is overexpressed in the mucosa of patients with CD\[[@B21],[@B22]\]. IFNγ is a pro-inflammatory cytokine that is essential for innate and adaptive immunity against infections\[[@B23]\]. Aberrant IFNγ expression is associated with a number of autoinflammatory and autoimmune diseases, including CD\[[@B24]\]. TLR2 is a type of cellular receptor mainly involved in innate immunity, which has been proposed as a mediator of a potential inborn response to gliadin\[[@B25]\]. MyD88 is an adapter protein mediating intracellular pathways triggered by TLRs to activate the transcription factor NF-κB\[[@B26]\]. Indeed, some gliadin peptides may bind TLR2 and drive the production of interleukin 1, a proinflammatory cytokine, through the mediation of MyD88\[[@B27]\]. Moreover, the MyD88 was found to be a key protein mediating the release of zonulin in response to gliadin, thus leading to an increase of mucosal permeability in CD\[[@B28]\]. Therefore, an increase of MyD88 may be considered as a marker of an alteration of intestinal barrier.

The aim of the present study was to investigate the duodenal mucosal transcriptomic expression of these four molecules in the prediction of ME underlying disorders at baseline, before a 2-year follow-up mean period, and to assess their potential accuracy in discriminating the development of CD and GS.

MATERIALS AND METHODS
=====================

Patients
--------

We retrospectively enrolled 89 consecutive patients with ME followed up for a mean period of two years until a diagnosis was reached. ME was defined according to the criteria of the Bucharest Consensus Conference\[[@B9]\].

Follow-up strategies which allowed achieving final diagnosis have been described elsewhere\[[@B18]\]. In detail, CD was diagnosed if duodenal biopsy showed a microscopic picture of Marsh 1 or higher, along with the positivity of IgA anti tissue transglutaminase 2 (anti-tTG2) antibodies, according to current guidelines\[[@B29]\]. The diagnosis of GS was made according to the Salerno criteria\[[@B30]\]. Patients with IBS fulfilled the Rome III criteria and underwent a series of investigations (serology for CD, full blood count, folate, vitamin B~12~, serum protein electrophoresis with immunoglobulin subclasses, stool investigations, fecal occult blood test, calprotectin, urea/lactose/glucose breath test and, if necessary, colonoscopy with random biopsy samples) in order to rule out organic diseases\[[@B31]\]. Finally, patients with established non-gluten related cause of ME (*Helicobacter pylori* infection, autoimmune disorders) were included.

We excluded subjects with immunoglobulin deficiencies, which may show possible molecular deregulation of duodenal mucosa. A group of 15 dyspeptic patients, undergoing upper endoscopy and duodenal biopsy without ME, represented the negative control group.

Histology and immunohistochemistry
----------------------------------

For each patient, formalin embedded biopsy samples of the duodenum performed at baseline were retrieved. Histological examination had been carried out on Hematoxylin-Eosin stained sections. Immunohistochemistry of CD3 lymphocytes had been performed using monoclonal murine antibody (Novocastra Leica Biosystems Ltd, Newcastle, United Kingdom), according to the manufacturer's instructions. In all subjects, IELs were counted in a field containing at least 1000 enterocytes and expressed as number per 100 enterocytes. We selected biopsy specimens with at least 15 IELs/100 enterocytes to define ME, as established in previous reports\[[@B17],[@B19]\]. The count was executed in the epithelial layer by two observers (DP and MGF) in a blinded fashion. Collection and processing was managed according to BRISQ recommendations\[[@B32]\].

Molecular analysis
------------------

Real time polymerase chain reaction (RT-PCR) was used to detect the amount of mRNA coding for tTG2, IFNγ, TLR2 and MyD88 in duodenal mucosa. As well-stated, mRNA levels were expressed as fold-change compared to controls. The relative expression of the studied gene levels was calculated with the 2^ΔΔCT^ method. RNA was extracted from at least 5, 10 μm sections of paraffin block using the RNeasy FFPE Kit (Qiagen, GmbH, Heidelberg, Germany), specifically designed for the purification of total RNA from formalin-fixed paraffin-embedded (FFPE) tissue sections, according to a validated protocol\[[@B33]\]. Five hundred microliters (μL) of xylene were added to the sections to yield a solution that was vortexed for 10s and then incubated for 10 min at room temperature (25 °C). This step was repeated twice. Subsequently, 500 μL of absolute ethanol was added and the novel solution was again vortexed vigorously for 10 s and centrifuged for 2 min at 11000 rpm in order to remove residual xylene. The supernatant was carefully removed by pipetting without disturbing the pellet. Finally, the mRNA concentrations were estimated by ultraviolet absorbance at 260/280 nm. We performed the agarose formaldehyde gel run to confirm the RNA integrity. Imaging analysis after this procedure was performed with the Bio-Rad Chemidoch Analyzer (Bio-Rad Laboratories S. r. l., Milan, Italy). Aliquots of total mRNA (1 mg) were reverse-transcribed using random hexamers and TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, United States) in a final volume of 50 μL. Two step reverse transcription PCR was performed using the firststrand cDNA with a final concentration of 1 × TaqMan gene expression assay, *i.e*., the analyzed molecules and glyceraldehyde 3 phosphate dehydrogenase as reference gene (Applied Biosystems, Foster City, CA). The final reaction volume was 25 μL and analyzed in triplicate (all experiments were repeated twice). A non template control (Rnase free water) was included on every plate. Our method was further validated by including in each assay fresh samples from three normal patients, frozen at -90 °C until the analysis. These samples were treated with the same technique as the paraffin embedded samples, except for the paraffin removal and rehydration procedures. Specific thermal cycler conditions were employed using a real time PCR System (Applied Biosystems). A standard curve plus validation experiment was performed for each primer/probe set. The reference gene was represented by glyceraldehydes3phosphate dehydrogenase. Primers and probes are reported in Table [1](#T1){ref-type="table"}.

###### 

Primers and probes

  -------------------------------------------
  Tissue transglutaminase 2
  Primer Forward:ATAAGTTAGCGCCGCTCTCC
  Primer Reverse: CGGTGGCTCCTTCCACTG
  Probe: GCCAGCCGCCAGTG
  Interferon gamma
  Primer Forward: CGCTTTACTTTATAGAAAACCTGGA
  Primer Reverse: TCAATGAAGAGAACTTGGTCATTC
  Probe: GCTTGAATCTAAA
  Toll-like receptor 2
  Primer Forward: CAAGATTCAAAGTATTTA
  Primer Reverse: CCAGGTG CATTTAAAGA
  Probe: TGCCCCTACTCAATCT
  MyD88
  Primer Forward: CAAGGCCTTGTCCCTGC
  Primer Reverse: TCTGCCCTGCCTCCT
  Probe: AGGCCCTGGGTGTGTGT
  -------------------------------------------

Statistical analysis
--------------------

Comparisons among continuous data obtained in our groups of patients were performed by one way analysis of variance (ANOVA) and Bonferroni's test as posthoc analysis to compare head-to head each group. The χ^2^ test was used for categorical variables. Values of *P* \< 0.05 were considered significant. Receiver operating curves (ROC) were drawn to estimate sensitivity and specificity of tTG2, IFNγ, TLR2 and MyD88. Correlations between IELs count, tTG2, IFNγ, TLR2 and MyD88 were assessed by Pearson's test. Diagnostic agreement for the IEL count was tested by calculating the weighted Cohen's *k* coefficient interpreted in accordance with the Landis and Koch benchmarks, whereby a value of more than 0.8 indicated excellent agreement. Statistical analyses were performed using the statistical software GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, United States).

RESULTS
=======

Patients baseline features
--------------------------

We enrolled 89 patients with ME. After the follow up the following diagnoses were observed: 31 CD, 17 GS, 29 IBS and 12 other non gluten-related ME. Among the 12 non gluten-related ME, 4 had small bowel Crohn's disease, 6 *H. pylori* infection, 1 scleroderma and 1 lymphocytic colitis. The most relevant clinical, demographic and histopathological characteristics are summarized in Table [2](#T2){ref-type="table"}. A good agreement among pathologists was achieved (*k* = 0.86, 95%CI: 0.75-0.91). The IELs count, DQ 2 or 8 positivity and the presence of weight loss, abdominal pain and diarrhea were the most important discriminating factors between CD, GS and non-gluten-related diseases (Table [2](#T2){ref-type="table"}). Villous atrophy (Marsh 3 stage) was found in 14 out of 31 CD patients, Marsh 2 in 3 and Marsh 1 in 14 patients.

###### 

Main demographic, clinical and pathologic features of enrolled patients

                           **Celiac disease** **(*n* = 31)**   **Gluten sensitivity** **(*n* = 17)**   **Irritable bowel syndrome** **(*n* = 29)**   **Other ME** **(*n* = 12)**   **Negative controls** **(*n* = 15)**   ***P* value**
  ------------------------ ----------------------------------- --------------------------------------- --------------------------------------------- ----------------------------- -------------------------------------- ------------------------------------------
  Age                      34 ± 12                             34.3 ± 6.1                              36.2 ± 13.4                                   34.7 ± 14.2                   32.6 ± 9.5                             0.89[1](#T2FN1){ref-type="table-fn"}
  Sex (F/M)                19/12                               15/2                                    22/7                                          11/1                          9/6                                    0.06[2](#T2FN2){ref-type="table-fn"}
  IELs count               51.6 ± 10.6                         18.6 ± 4.9                              15.5 ± 5.1                                    19.0 ± 7.6                    5.3 ± 1.5                              \< 0.001[1](#T2FN1){ref-type="table-fn"}
  Weight loss              19 (61.3)                           7 (41.2)                                4 (13.8)                                      6 (50)                        0                                      0.002[2](#T2FN2){ref-type="table-fn"}
  Abdominal pain           25 (80.6)                           16 (94.1)                               28 (96.5)                                     8 (66.6)                      0                                      0.04[2](#T2FN2){ref-type="table-fn"}
  Diarrhea                 21 (67.7)                           6 (35.3)                                29 (100)                                      6 (50)                        0                                      \< 0.001[2](#T2FN2){ref-type="table-fn"}
  Weakness                 14 (45.1)                           8 (47.0)                                8 (27.6)                                      3 (25)                        0                                      0.09[2](#T2FN2){ref-type="table-fn"}
  Headache                 2 (6.5)                             7 (41.2)                                4 (13.8)                                      0 (0)                         0                                      0.73[2](#T2FN2){ref-type="table-fn"}
  DQ 2-8                   29 (93.5)                           10 (58.8)                               11 (37.9)                                     0 (0)                         NA                                     \< 0.001[2](#T2FN2){ref-type="table-fn"}
  Iron deficiency anemia   8 (25.8)                            2 (11.8)                                2 (6.9)                                       8 (66.6)                      0                                      0.63[2](#T2FN2){ref-type="table-fn"}

ANOVA test;

χ^2^ test for trend. NA: Not available.

tTG2
----

The mucosal expression of mRNA-tTG2 is represented in Figure [1A](#F1){ref-type="fig"}. In detail, CD patients had the highest levels (8.3 ± 4.5) compared to GS (3.6 ± 2.7), IBS (3.5 ± 1.8), other ME (5.3 ± 2.3) and negative controls (1.001 ± 0.089). The ANOVA plus Bonferroni analysis showed that CD \> Other ME \> GS = IBS \> negative controls.

![Pattern of mucosal expression of tTG2-mRNA in subjects with different causes of microscopic enteritis. A: ANOVA plus Bonferroni analysis showed that CD \> Other ME \> GS = IBS \> negative controls, ^a^*P* \< 0.05, ^c^*P* \< 0.001; B: ROC curve of CD *vs* GS comparison is reported. ROC: Receiver operating curves.](WJG-22-8017-g001){#F1}

The ROC curve analysis, displayed in Figure [1B](#F1){ref-type="fig"} showed that a cut off of 2.258 was able to discriminate between CD and GS with a low sensitivity (52.94%) and a good specificity (87.1%; AUC = 0.804).

IFNγ
----

The mucosal expression of mRNA-IFNγ is displayed in Figure [2A](#F2){ref-type="fig"}. We observed that CD patients had the highest levels (8.5 ± 4.1) compared to GS (3.3 ± 2.8), IBS (3.3 ± 2.6), other ME (4.6 ± 2.1) and negative controls (1.001 ± 0.15). The ANOVA plus Bonferroni analysis showed that CD \> Other ME \> GS = IBS \> negative controls.

![Pattern of mucosal expression of interferon gammaγ-mRNA in subjects with different causes of microscopic enteritis. A: ANOVA plus Bonferroni analysis showed that CD \> Other ME \> GS = IBS \> negative control, ^a^*P* \< 0.05, ^c^*P* \< 0.001; B: ROC curve of CD *vs* GS comparison is reported. ROC: Receiver operating curves.](WJG-22-8017-g002){#F2}

The analysis of ROC curve (Figure [2B](#F2){ref-type="fig"}) showed that a cut off of 1.853 was able to differentiate CD and GS with a sensitivity of 47.06% and a specificity of 96.77%, with an AUC of 0.816.

TLR2
----

The mucosal expression of mRNA-TLR2 is represented in Figure [3](#F3){ref-type="fig"}. Patients with non gluten-related causes of ME were characterized by the highest levels (6.1 ± 1.9), greater than GS (3.1 ± 1.8), IBS (3.5 ± 2.0), CD (4.1 ± 2.4) and negative controls (1.006 ± 0.18). The ANOVA plus Bonferroni analysis showed that Other ME \> CD = GS = IBS \> negative controls.

![Pattern of mucosal expression of toll-like receptor 2-mRNA in subjects with different causes of microscopic enteritis. ANOVA plus Bonferroni analysis showed that Other ME \> CD = GS = IBS \> negative controls, ^a^*P* \< 0.05, ^b^*P* \< 0.01.](WJG-22-8017-g003){#F3}

MyD88
-----

The mucosal expression of mRNA-MyD88 is represented in Figure [4A](#F4){ref-type="fig"}. Patients with CD expressed levels similar as non gluten-related causes of ME (7.8 ± 4.9 and 6.7 ± 2.9), higher than GS (4.2 ± 2.3), IBS (4.3 ± 2.4), and negative controls (0.99 ± 0.17). The ANOVA plus Bonferroni analysis demonstrated that CD = Other ME \> GS = IBS \> negative controls.

![Pattern of mucosal expression of MyD88-mRNA in subjects with different causes of duodenal lymphocytosis. A: ANOVA plus Bonferroni analysis showed that CD = Other ME \> GS = IBS \> negative controls, ^b^*P* \< 0.01; B: ROC curve of CD *vs* GS comparison is reported. ROC: Receiver operating curves.](WJG-22-8017-g004){#F4}

The analysis of ROC curve (Figure [4B](#F4){ref-type="fig"}) showed that a cut off of 3.722 was able to differentiate CD and GS with a sensitivity of 52.94% and a specificity of 74.19%, with an AUC of 0.712.

Correlation between IELs count and transcriptome analysis
---------------------------------------------------------

In all cases, the IELs count correlated with mRNA levels with a strong significance (*P* \< 0.0001). The expression of tTG2 directly correlated to IELs (*r* = 0.66, 95%CI: 0.53-0.76). IFNγ showed a similar pattern, with an *r* = 0.56, 95%CI: 0.42-0.68. A less relevant, despite significant correlation, was found for TLR2 (*r* = 0.32, 95%CI: 0.13-0.48) and for MyD88 (*r* = 0.49, 95%CI: 0.33-0.63).

DISCUSSION
==========

ME often represents a diagnostic dilemma, therefore a careful algorithm should be applied in such cases to achieve the final diagnosis\[[@B9],[@B18]\]. IELs infiltrate represents the only common denominator; therefore, in our series we selected only subjects showing IELs levels higher than 15/100 enterocytes, independently from ME etiology. This cut-off value was associated with molecular mucosal changes suggestive of inflammatory damage/repair in our experience\[[@B20]\]. IELs infiltrate is a well known feature of GS and CD\[[@B34],[@B35]\], but it has been described even in patients with duodenal involvement in systemic disorders\[[@B36]\]. IBS may show an increased IELs infiltrate, thus confirming that it cannot be considered only as a functional entity\[[@B37]\]. In a previous experience of our group, we demonstrated a positive correlation between the amount of IELs infiltrate and the mucosal expression of tTG2 and IFNγ in patients with seronegative suspected CD\[[@B20],[@B38]\]. In the present study, moreover, we confirmed that IELs infiltrate parallels mucosal molecular expression, more markedly for tTG2 and IFNγ, but also for TLR2 and MyD88. Therefore, our results demonstrate that ME clearly underlies a local inflammatory status.

tTG2 is the main autoantigen involved in CD pathogenesis\[[@B21]\], however it is an enzyme essential for the process of wound healing and tissue reparation, since it is able to create crosslinks between peptides\[[@B39]\]. For this reason, tTG2 is over-expressed not only in gluten-related disorders, but even in all pathological conditions that induce mucosal injury, as confirmed in the present study. In our analysis, we reported that tTG2 has a good performance in the comparison between CD and GS or IBS. This detail could be useful especially in the subgroup of subjects with IBS who show positivity of anti-tTG antibodies, without histological evidence of CD\[[@B40]\]. Moreover, our result may explain the reason of a four-fold increased risk of CD in subjects with IBS\[[@B41]\]. A pattern similar to tTG was found for IFNγ. Indeed, patients with CD show the upregulation of IELs-secreted IFNγ. This ability has been demonstrated even in peripheral T lymphocytes of CD patients, which are able to produce high IFNγ levels when stimulated by gliadin peptides\[[@B42],[@B43]\]. For these reasons, tTG2 and IFNγ could represent a good diagnostic tool in gluten related-disorders. In summary, we found a high specificity of tTG2 and IFNγ, despite an expected low sensitivity, in discriminating CD from GS development. The expression of these molecules in GS has been poorly explored until now and available data are controversial. Some reports have shown an IFNγ overexpression in GS similar to CD\[[@B44]\], while others described a marked increase only in CD\[[@B19]\]. In the present study, we have found that high levels of IFNγ are more predictive of CD than GS.

TLR2 is a receptor involved in the innate immune response against non-self antigens. It has been demonstrated that some gliadin peptides may bind such receptor and address the production of interleukin 1, a proinflammatory cytokine, trough the mediation of MyD88\[[@B27]\]. Moreover, MyD88 was found to be a key protein mediating the release of zonulin in response to gliadin, thus leading to an increase of mucosal permeability in CD\[[@B28]\]. In a previous report\[[@B19]\], patients with GS expressed higher levels of TLR2 than subjects with CD. However, we found that ME had similar baseline mRNA levels encoding for TLR2, independently from the successive development of CD or GS within a two-year period. Surprisingly, in our series, non gluten related ME had the highest levels of TLR2. This finding could be related to the deep deregulation of TLRs, which has been described in IBD (a possible cause of non gluten related ME). Indeed, such receptors mediate the immune response against the microbiota, a phenomenon that has been claimed as a trigger in IBD pathogenesis\[[@B45]-[@B47]\].

In regard to the molecular pattern of MyD88, similarly to TLR2, we found that patients with non gluten related causes of ME showed higher levels than IBS and GS, but comparable with CD. This finding suggests that a potential increase of intestinal permeability may be more marked when a severe intestinal damage underlies ME. On the other hand, MyD88 has been poorly investigated in CD. Eiró et al\[[@B48]\] demonstrated that its increased expression paralleled mucosal TLR4 in CD. Therefore, MyD88 overexpression overtaking TLR2 may be explained by a MyD88-independent pathway for TLR2 in CD, as described by Junker et al\[[@B25]\].

In conclusion, our results suggest that a single marker is unable to discriminate the development of different ME underlying conditions as well as between CD and GS. High mucosal levels of tTG and IFNγ mRNA may predict the development of CD more than GS with high specificity. TLR2 does not discriminate the development of CD from GS. High MyD88 levels may indicate that intestinal permeability is more increased when a severe intestinal damage underlies ME (CD as well as Crohn's disease). Finally, a reliable marker for GS diagnosis has not yet been found; however, further studies need to be addressed to evaluate whether the combination of different mucosal markers could help the differential diagnosis with CD and support the identification of doubtful cases of GS\[[@B49],[@B50]\]. Therefore, the results of the present paper do not seem to show a clear translational value.
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